NOVARTIS Forschungsinstitut Vienna and
* AKH Vienna, Department for Blood Serology and Transfusion Medicine, University of Vienna, Vienna, Austria
Correspondence: Dr. Markus Dettke, AKH Vienna, Department for Blood Serology and Transfusion Medicine, Währinger Gürtel 18-20, A-1090 Vienna, Austria. E-mail: markus.dettke{at}univie.ac.at
|
|
|---|
Key Words: granulocytes Lewis Y antigen CD66 nonspecific-crossreacting antigen
|
|
|---|
Although the expression of LeX and sLeX on human granulocytes is well established, less is known about the expression of the difucosyl form of the type II precursor chain, LeY. Originally detected and characterized as an oligosaccharide expressed on mucins of an ovarian cyst adenoma [4 ], the LeY determinant has been identified as an oncofetal carbohydrate antigen related to ontogenesis [5 ], cellular apoptosis [6 , 7 ], and human cancer [8 , 9 ]. Less is known, however, about the physiological role of LeY.
There is evidence that LeY is involved in the process of cellular
adhesion and cellular motility [10
]. Monoclonal
antibodies (mAbs) directed against LeY or a related parietal structure
(i.e., Fuc
1
2Galß1
R, which is shared by H/LeY/LeB antigens)
were shown to inhibit locomotion of LeY-bearing tumor cells in
vitro [11
, 12
]. Moreover, in the mouse
model, LeY seemed to act as a mediator molecule essential for the
initial stage of embryo implantation [13
,
14
].
Despite its expression on various types of human cancer, recent data indicate that the LeY determinant is also expressed on cells of the hematopoietic system. Muroi et al. [15 ] demonstrated the expression of the LeY hapten on matured peripheral blood cells and various leucemic cell lines, as identified by the reactivity with the anti-LeY mAb AH-6. Using a panel of different anti-LeY mAbs, Kitamura et al. [16 ] confirmed the expression of the LeY oligosaccharide on circulating blood cells, even if in this study the expression of LeY was restricted to granulocytes. Under certain pathological circumstances, the LeY is also expressed on cells of lymphoid lineage, e.g., human immunodeficiency virus (HIV)-infected lymphocytes [17 ].
In the present study, we analyzed the expression and regulation of the LeY oligosaccharide on peripheral blood cells, as defined by the reactivity with the anti-LeY mAb ABL 364. Our data showed that in the human peripheral blood, granulocytes represent the only cells expressing LeY. Although LeY expression was weak on resting granulocytes, in vitro challenge with formyl-Met-Leu-Phe (fMLP) led to a rapid increase in granulocyte LeY expression, which seemed to be related to an increased expression of the CD66 antigens on the granulocyte membrane surface.
|
|
|---|
Sample collection and preparation
Human anticoagulated whole blood was obtained from 12 different
healthy donors. Peripheral polynuclear granulocytes were separated by
density-gradient centrifugation and an additional sedimentation step
(6% dextran) to remove contaminating erythrocytes. Isolated
neutrophils were resuspended in RPMI 1640 supplemented with 10% fetal
calf serum (FCS; Gibco, Santa Clara, CA). The purity of isolated
granulocytes was >90%, as assessed by fluorescence labeling with the
anti-CD66b mAb 80H3 (Immunotech, Marseille, France). To block
nonspecific Fc receptor-mediated binding of test mAbs in experiments
performed with isolated granulocytes, purified human immunoglobulin G
(IgG; 500 µg/ml; Sigma, St. Louis, MO) was added to the cell
suspension.
Immunoflourescence-staining procedure
Immunofluorescence labeling was performed by incubation of whole
blood (100 µl) or isolated granulocytes (1x105 cells)
with at least three different concentrations (0.5, 1, 2 µg/sample) of
the anti-LeY mAb ABL 364 or its respective F(ab)'2 fragment
for 30 min on ice. After washing in phosphate-buffered saline (PBS)
def/10% FCS, cells were stained for 30 min with fluorescein
isothiocyanate (FITC)-conjugated F(ab)'2 fragments of sheep
anti-mouse IgG3 (Southern Biotechnology Associates, Birmingham, AL). In
the case of whole blood, the different leukocyte subpopulations were
stained with phycoerythrin (PE)-conjugated mIgG1 anti-CD mAbs specific
for CD3, CD14, CD19 (Becton Dickinson, Rutherford, NJ), and CD66
(Monosan, Uden, The Netherlands). After washing and in the case of
whole blood samples after lysis of erythrocytes by ammonium chloride,
the leukocytes were fixed with 1% paraformaldehyde PBS. Flow
cytometric analysis was performed on a FACScan cytofluorimeter (Becton
Dickinson). At least 40,000 cells were counted in each sample. In
competitive binding experiments, various concentrations (1, 5 µg/ml)
of the neoglycoproteins LeY-BSA or LeX-BSA (Chembiomed, Edmonton,
Canada) were added to ABL 364-labeled granulocytes, and the decrease in
the membrane fluorescence intensity was monitored by
fluorescein-activated cell sorter (FACS).
In vitro activation of isolated granulocytes
For in vitro activation, isolated granulocytes
(1x106 cells) were suspended in RPMI 1640/10% FCS and
incubated with different concentrations (10-9
M10-6 M) of the chemotactic peptide fMLP
(Sigma). After varying periods of incubation at 37°C (560 min), the
cells were washed, fixed, and stained for FACS analysis.
Immunoprecipitation and immunoblotting
Immunoprecipitation of nonspecific crossreacting antigens (NCAs)
was performed with mAb CLB gran/10 recognizing NCA-160/90 (Monosan) and
anti-NCA-95 mAb 80H3 (Immunotech). The specificity of both mAbs for the
respective glycoproteins has been described [20
]. Sham
precipitates were performed with anti-CD3 mAb (Becton Dickinson). All
mAbs were coupled to sheep anti-mIgG, chemically crosslinked to protein
A-Sepharose beads (Bio-Rad, München, Germany). Lysis of isolated
neutrophils (109 cells) was performed in PBS medium
containing 0.5% Nonidet P-40 (NP-40), 5 mM ethylenediaminetetraacetate
(EDTA), 1 mM diisopropyl fluorophosphate, and 0.5 mM
phenylmethylsulfonyl flouride (Sigma). After a preclearing step with
irrelevant mIgG coupled to protein A-Sepharose (Sigma),
immunoprecipitation was carried out overnight at 4°C. Thereafter, the
samples were run with reduced 510% sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and
electrophoretically transferred to nitrocellulose membranes. After
blocking with BSA (1% BSA in 10 mM Tris-HCl, 150 mM NaCl, 0.05% Tween
20, pH 8.0), the nitrocellulose sheets were incubated for 1 h with
mAb ABL 364 (
10 µg/ml). After incubation with a horseradish
peroxidase-conjugated anti-mIgG mAb (Bio-Rad), bound mAbs were detected
by chemiluminescence (Amersham, Amersham, England).
Crossed-immunoprecipitation enzyme-linked immunosorbent assay
(ELISA)
For crossed immunoprecipitation ELISA, the precleared NP-40
granulocyte extract was exposed to the wells of a microtiter ELISA
plate precoated overnight (4°C) with 2 µg/well of anti-CD66 mAbs or
isotype control mAbs. The plates were incubated for 2 h at room
temperature and washed, and mAb ABL 364 was added at a final
concentration of 0.5 µg/well for 2 h. After incubation with
peroxidase-conjugated anti-mIgG3 antibody (Southern Biotechnology;
1:1000 in PBS def./10% FCS), the plates were developed using
O-phenylenediamine dihydrochloride as substrate (Sigma).
|
|
|---|
![]() View larger version (34K): [in a new window] |
Figure 1. Representative dual-color fluorescence histograms of a healthy donor
after staining of whole blood cells with anti-LeY mAb ABL 364. A, cell
control; B, control mIgG1-PE vs. control mIgG3 + anti-IgG3-FITC;
C, anti-CD3-PE vs. ABL 364 + anti-IgG3-FITC; D, anti-CD14-PE vs.
ABL 364 + anti-IgG3-FITC; E, anti-CD19-PE vs. ABL 364 +
anti-IgG3-FITC; F, anti-CD66-PE vs. ABL 364 + anti-IgG3-FITC.
|
|
View this table: [in a new window] |
Table 1. Competition of LeY- or LeX-conjugated neoglycoproteins for binding of
mAb ABL364 to the granulocyte membrane surface
|
![]() View larger version (11K): [in a new window] |
Figure 2. Increased expression of LeY reactivity after stimulation of
isolated granulocytes with fMLP. A, Dose-response curve of LeY
antigenic reactivity after stimulation with varying concentrations of
fMLP (10-910-6 M);
B, kinetic of the observed augmentation of the granulocyte LeY
expression. , Granulocyte LeY after activation with fMLP
(10-7 M); , granulocyte MFI obtained after
staining with mAb ABL 364 without activation. Data shown are expressed
as mean ± SD of three independent experiments.
|
To estimate the expression of the LeY oligosaccharide on NCAs, we performed a series of immunoprecipitation experiments to determine whether anti-LeY mAb ABL 364 would bind to detergent-solubilized neutrophil membrane extracts precipitated by mAb CLB gran/10 (which recognize NCA 160/90) or mAb 80H3 (defining NCA-95). After SDS-PAGE, followed by immunoblotting, ABL 364 stained the 160/90-kD protein bands precipitated by mAb CLB gran/10 and the 95-kD protein band precipitated by mAb 80H3 (Fig. 3 ). However, the reactivity toward the 80H3-precipitate was weak compared with the CLB gran/10 precipitate. Similar data were also obtained in a crossed-immunoprecipitation ELISA (unpublished results), therefore confirming the previously suggested differences in the glycosylation pattern of various members of the CD66 antigens [27 ].
![]() View larger version (99K): [in a new window] |
Figure 3. Immunoblot of the granulocyte NCAs obtained after precipitation with
mAb 80H3, mAb CLB gran/10, or control (anti-CD3) mAb and probed with
mAb ABL 364. The gel was run under reduced condition. The relative
positions of the Mr markers are indicated at left
(x1000).
|
Received July 21, 1999; revised March 30, 2000; accepted April 10, 2000.
|
|
|---|
-ß2) on human granulocytes J. Leukoc. Biol. 53,541-549[Abstract]This article has been cited by other articles:
![]() |
C.-S. Shi, G.-Y. Shi, S.-M. Hsiao, Y.-C. Kao, K.-L. Kuo, C.-Y. Ma, C.-H. Kuo, B.-I. Chang, C.-F. Chang, C.-H. Lin, et al. Lectin-like domain of thrombomodulin binds to its specific ligand Lewis Y antigen and neutralizes lipopolysaccharide-induced inflammatory response Blood, November 1, 2008; 112(9): 3661 - 3670. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Nystrom, A. Grahn, M. Lindh, M. Brytting, U. Mandel, G. Larson, and S. Olofsson Virus-induced transcriptional activation of host FUT genes associated with neo-expression of Ley in cytomegalovirus-infected and sialyl-Lex in varicella-zoster virus-infected diploid human cells Glycobiology, April 1, 2007; 17(4): 355 - 366. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Brodzik, M. Glogowska, K. Bandurska, M. Okulicz, D. Deka, K. Ko, J. van der Linden, J. H. W. Leusen, N. Pogrebnyak, M. Golovkin, et al. Plant-derived anti-Lewis Y mAb exhibits biological activities for efficient immunotherapy against human cancer cells PNAS, June 6, 2006; 103(23): 8804 - 8809. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Westwood, M. J. Smyth, M. W. L. Teng, M. Moeller, J. A. Trapani, A. M. Scott, F. E. Smyth, G. A. Cartwright, B. E. Power, D. Honemann, et al. Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice PNAS, December 27, 2005; 102(52): 19051 - 19056. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. P.J.M. van Gisbergen, M. Sanchez-Hernandez, T. B.H. Geijtenbeek, and Y. van Kooyk Neutrophils mediate immune modulation of dendritic cells through glycosylation-dependent interactions between Mac-1 and DC-SIGN J. Exp. Med., April 18, 2005; 201(8): 1281 - 1292. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Klinger, H. Farhan, H. Just, H. Drobny, G. Himmler, H. Loibner, G. C. Mudde, M. Freissmuth, and V. Sexl Antibodies Directed against Lewis-Y Antigen Inhibit Signaling of Lewis-Y Modified ErbB Receptors Cancer Res., February 1, 2004; 64(3): 1087 - 1093. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Dettke, G. Palfi, E. Pursch, M. B. Fischer, and H. Loibner Increased expression of the blood group-related Lewis Y antigen on synovial fluid granulocytes of patients with arthritic joint diseases Rheumatology, September 1, 2001; 40(9): 1033 - 1037. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||